Summary & Overview
HCPCS J1330: Injection, Ergonovine Maleate, up to 0.2 mg
HCPCS Level II code J1330 designates an injection of ergonovine maleate, up to 0.2 mg, a uterotonic medication used primarily in obstetric care to manage uterine atony and postpartum hemorrhage. As a drug administration code, J1330 is relevant to hospitals, labor and delivery units, ambulatory surgical centers, and any facility providing injectable uterotonic therapy. Nationally, accurate coding of injectable medications affects drug billing, inventory tracking, and clinical documentation tied to maternal safety.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J1330 represents clinically and operationally, common payer coverage considerations, and the types of benchmarks and policy elements typically assessed for HCPCS drug codes. The publication outlines payment and billing context, typical sites of service, and the role of J1330 within obstetric medication management. It also notes where input data are not available for specific fields such as associated taxonomies, ICD-10 diagnoses, and related codes. This summary equips revenue cycle professionals, coding specialists, and clinical leaders with the foundational information needed to locate further payer policies and reimbursement guidance for J1330.
Billing Code Overview
HCPCS Level II code J1330 represents an injection of ergonovine maleate, up to 0.2 mg. This entry describes a medication administration service for a uterotonic agent commonly used in obstetric settings to manage uterine tone.
Service Type: Medication injection / drug administration
Typical Site of Service: Hospital inpatient or outpatient obstetric unit, labor and delivery, or ambulatory surgical center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves a postpartum patient who experiences uterine atony with excessive vaginal bleeding following vaginal delivery or cesarean delivery. The obstetric team identifies subinvolution of the uterus or refractory hemorrhage after initial uterotonic agents (such as oxytocin) and administers an intramuscular or intramyometrial injection of ergonovine maleate (J1330) as part of uterotonic therapy. The clinical workflow includes immediate assessment of maternal vital signs, uterine massage, IV access, laboratory evaluation (type and crossmatch, complete blood count), and escalation to additional uterotonics or surgical interventions if bleeding persists. Documentation should include indication for use (e.g., postpartum hemorrhage due to uterine atony), dose administered (up to 0.2 mg per J1330), route, time, patient response, and any adverse effects such as hypertension or nausea. Billing should link J1330 to the specific delivery encounter and the related ICD-10 diagnosis code(s) that justify use of an ergot alkaloid for uterine atony or postpartum hemorrhage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typically required (e.g., complicated management of hemorrhage requiring extended time documenting additional interventions when billing supports increased work). |